Medigene expands end-to-end technology platform through worldwide, exclusive license of a CD40L-CD28 Costimulatory Switch Receptor further enhancing potential to treat solid tumors
02 mai 2023 02h30 HE
|
Medigene AG
Medigene accelerates the expansion of its end-to-end platform of multiple, combinable, exclusive and proprietary technologies with the potential to create best-in-class T cell receptor engineered T...
Medigene AG to Present Expitope 3.0 at the 20th Annual Meeting of the Association for Cancer Immunotherapy (CIMT)
27 avr. 2023 05h00 HE
|
Medigene AG
Martinsried/Munich, April 27, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Medigene AG presents final Phase I data of TCR-T cell therapy MDG1011 in patients with high-risk blood cancers
24 avr. 2023 05h00 HE
|
Medigene AG
MDG1011 was generally well tolerated in nine heavily pre-treated patients across three ascending dose levelsNo neurotoxicity or dose-limiting toxicities observedTwo out of nine patients showed early...
New data presented at AACR Annual Meeting demonstrates significantly enhanced anti-solid tumor effects of T cells co-expressing an optimal affinity TCR targeting NY-ESO-1 and a PD1-41BB co-stimulatory switch receptor (MDG1015)
18 avr. 2023 09h30 HE
|
Medigene AG
Martinsried/Munich, April 18, 2023, Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Medigene AG to present Phase I clinical data for MDG1011 with poster presentation at EBMT 2023 Annual Meeting
11 avr. 2023 10h45 HE
|
Medigene AG
Martinsried/Munich, April 11, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Medigene AG Presents Systematic and Sequential, End-To-End Platform Approach to Optimize TCR-T Therapy Development
04 avr. 2023 10h00 HE
|
Medigene AG
Martinsried/Munich, April 04, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard) is an early-stage immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene enters Cooperative Research and Development Agreement with the National Cancer Institute to evaluate the use of Medigene’s proprietary T cell receptors in novel cell constructs
03 avr. 2023 12h45 HE
|
Medigene AG
Martinsried/Munich, April 3, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG Reports Full-Year 2022 Financial Results and Provides Corporate Update
29 mars 2023 01h30 HE
|
Medigene AG
Continued progress in 2022 with corporate strategy update, end-to-end platform innovation, pipeline expansion, and acceleration of lead candidate developmentPartnering momentum continues with a $3...
Medigene AG to present at the 4th TCR-based Therapies for Solid Tumors Summit in Boston
28 mars 2023 11h00 HE
|
Medigene AG
Martinsried/Munich, March 28, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG Announces Appointment of Dr. Kirsty Crame, MD, as Head of Clinical Research & Development
20 mars 2023 06h00 HE
|
Medigene AG
Martinsried/Munich, March 20, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell...